Cytognos is a Biotech company based in Salamanca with over 20 years of experience at successfully designing, developing, manufacturing and commercializing innovative flow cytometry products for in vitro diagnostics (IVD) and life science research use only (RUO). Cytognos´ growth strategy has been based on bringing to the market exclusive technologies transferred by research centres and universities, these innovative products have allowed Cytognos to become a reference point, providing world-class products developed to address gaps within the current multicolour flow cytometry workflow.

Cytognos collaborates actively with the EuroFlow™ consortium implementing and bringing onto the market the Next Generation Flow™ approach which provides high sensitive flow cytometry tests and standardized protocols for the diagnosis, classification and follow-up of haematological malignancies, Minimal Residual Disease detection and Primary Immunodeficiencies.


Cytognos S.L is certified by the ISO 13485 for Medical Devices, therefore we offer the best quality products and guarantee compliance with the applicable regulatory requirements.

Our certification by ISO 9001 allows us to keep improving products, achieve customer’s satisfaction and meet any requirement of our stakeholders. Products and services given by external suppliers might affect directly our company activity. For this reason, Cytognos S.L informs suppliers that they will be evaluated. This evaluation will be based on specific criteria previously defined according to a risk assessment performed by Cytognos. Also, Cytognos will monitor suppliers continuously as well as their compliance based on defined requirements for ordered products and/or services.

These certificates and our Quality Policy are available below:

  • ISO 9001 Quality Management Systems. Requirements
  • ISO 13485 Medical Devices. Quality Management Systems. Requirements for regulatory purposes
  • Quality Policy

Our products

Next Generation Flow Solutions
EuroFlow™ reagents
Acute Leukemia
Chronic Lymphoproliferative Disorders
Plasma Cell Dyscrasias
Primary Immunodeficiencies

Useful information

Cytognos technology
Minimal Residual Disease
Clinical trials
Scheduled webinars


HyperCyte Biomedical CO.,LTD
Tel: (8610)8313-1025
QQ: 2428012469